BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365-1372. [PMID: 12237282 DOI: 10.1093/jnci/94.18.1365] [Cited by in Crossref: 470] [Cited by in F6Publishing: 358] [Article Influence: 24.7] [Reference Citation Analysis]
Number Citing Articles
1 Armstrong K, Weber B, Ubel PA, Peters N, Holmes J, Schwartz JS. Individualized Survival Curves Improve Satisfaction With Cancer Risk Management Decisions in Women With BRCA1/2 Mutations. JCO 2005;23:9319-28. [DOI: 10.1200/jco.2005.06.119] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
2 Lourenço JJ, Vargas FR, Bines J, Santos EM, Lasmar CAP, Costa CH, Teixeira EMB, Maia MCM, Coura F, Silva CHD, Moreira MAM. BRCA1 mutations in Brazilian patients. Genet Mol Biol 2004;27:500-4. [DOI: 10.1590/s1415-47572004000400006] [Cited by in Crossref: 13] [Article Influence: 0.8] [Reference Citation Analysis]
3 Beckmann M, Bani M, Fasching P, Strick R, Lux M. Risk and risk assessment for breast cancer: Molecular and clinical aspects. Maturitas 2007;57:56-60. [DOI: 10.1016/j.maturitas.2007.02.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
4 Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med 2011;13:998-1005. [PMID: 21811163 DOI: 10.1097/GIM.0b013e318226fc15] [Cited by in Crossref: 86] [Cited by in F6Publishing: 34] [Article Influence: 9.6] [Reference Citation Analysis]
5 Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Llacuachaqui M, Chornokur G, Ping S, Narod SA;  Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014;110:530-534. [PMID: 24292448 DOI: 10.1038/bjc.2013.741] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
6 Karlan BY, Berchuck A, Mutch D. The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice. Obstetrics & Gynecology 2007;110:155-67. [DOI: 10.1097/01.aog.0000269050.79143.84] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
7 Kowalski T, Siddiqui A, Loren D, Mertz HR, Mallat D, Haddad N, Malhotra N, Sadowski B, Lybik MJ, Patel SN, Okoh E, Rosenkranz L, Karasik M, Golioto M, Linder J, Catalano MF, Al-Haddad MA. Management of Patients With Pancreatic Cysts: Analysis of Possible False-Negative Cases of Malignancy. J Clin Gastroenterol. 2016;50:649-657. [PMID: 27332745 DOI: 10.1097/mcg.0000000000000577] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
8 Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van ‘t Veer L. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23:7804-7810. [PMID: 16219936 DOI: 10.1200/jco.2004.00.8151] [Cited by in Crossref: 295] [Cited by in F6Publishing: 53] [Article Influence: 18.4] [Reference Citation Analysis]
9 Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers. JCO 2005;23:8629-35. [DOI: 10.1200/jco.2005.02.9199] [Cited by in Crossref: 108] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
10 Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222-4227. [PMID: 14615451 DOI: 10.1200/jco.2003.04.131] [Cited by in Crossref: 146] [Cited by in F6Publishing: 34] [Article Influence: 8.1] [Reference Citation Analysis]
11 Moreira L, Castells A. Surveillance of patients with hereditary gastrointestinal cancer syndromes. Best Pract Res Clin Gastroenterol 2016;30:923-35. [PMID: 27938787 DOI: 10.1016/j.bpg.2016.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020;12:2731-2742. [PMID: 32368150 DOI: 10.2147/cmar.s211151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
13 Mitchell R, Buckingham L, Cobleigh M, Rotmensch J, Burgess K, Usha L. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One 2018;13:e0195497. [PMID: 29659587 DOI: 10.1371/journal.pone.0195497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
14 Kamran MW, Vaughan D, Crosby D, Wahab NA, Saadeh FA, Gleeson N. Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC). Eur J Obstet Gynecol Reprod Biol 2013;170:251-4. [PMID: 23880597 DOI: 10.1016/j.ejogrb.2013.06.030] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
15 Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95. [PMID: 12712470 DOI: 10.1002/cncr.11310] [Cited by in Crossref: 316] [Cited by in F6Publishing: 265] [Article Influence: 17.6] [Reference Citation Analysis]
16 Barker SD, Bale S, Booker J, Buller A, Das S, Friedman K, Godwin AK, Grody WW, Highsmith E, Kant JA, Lyon E, Mao R, Monaghan KG, Payne DA, Pratt VM, Schrijver I, Shrimpton AE, Spector E, Telatar M, Toji L, Weck K, Zehnbauer B, Kalman LV. Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing. J Mol Diagn 2009;11:553-61. [PMID: 19767587 DOI: 10.2353/jmoldx.2009.090078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
17 Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat 2009;117:497-504. [PMID: 18821011 DOI: 10.1007/s10549-008-0190-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
18 Liu Y, Yen HY, Austria T, Pettersson J, Peti-Peterdi J, Maxson R, Widschwendter M, Dubeau L. A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State. EBioMedicine 2015;2:1318-30. [PMID: 26629527 DOI: 10.1016/j.ebiom.2015.08.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L. Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. Cancers (Basel) 2019;11:E193. [PMID: 30736435 DOI: 10.3390/cancers11020193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
20 Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol 2013;717:71-83. [PMID: 23545364 DOI: 10.1016/j.ejphar.2013.03.037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
21 Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16:241-260. [PMID: 17508274 DOI: 10.1007/s10897-007-9090-7] [Cited by in Crossref: 136] [Cited by in F6Publishing: 98] [Article Influence: 9.7] [Reference Citation Analysis]
22 Lee YC, Lee YC, Li CY, Lee YL, Chen BL. BRCA1 and BRCA2 Gene Mutations and Lung Cancer Sisk: A Meta-Analysis. Medicina (Kaunas) 2020;56:E212. [PMID: 32349445 DOI: 10.3390/medicina56050212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Eitan R, Michaelson-cohen R, Levavi H, Beller U. The Counseling and Management of Young Healthy BRCA Mutation Carriers: . International Journal of Gynecological Cancer 2009;19:1156-9. [DOI: 10.1111/igc.0b013e3181b33c4a] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. American Journal of Obstetrics and Gynecology 2006;194:1702-9. [DOI: 10.1016/j.ajog.2006.03.006] [Cited by in Crossref: 74] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
25 Sikdar N, Saha G, Dutta A, Ghosh S, Shrikhande SV, Banerjee S. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview. Curr Genomics 2018;19:444-63. [PMID: 30258276 DOI: 10.2174/1389202919666180221160753] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
26 Daly MB. The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling. J Genet Couns 2009;18:42-8. [PMID: 18688698 DOI: 10.1007/s10897-008-9183-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
27 Bradbury AR, Dignam JJ, Ibe CN, Auh SL, Hlubocky FJ, Cummings SA, White M, Olopade OI, Daugherty CK. How Often Do BRCA Mutation Carriers Tell Their Young Children of the Family's Risk for Cancer? A Study of Parental Disclosure of BRCA Mutations to Minors and Young Adults. JCO 2007;25:3705-11. [DOI: 10.1200/jco.2006.09.1900] [Cited by in Crossref: 65] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
28 Hoskins LM, Roy K, Peters JA, Loud JT, Greene MH. Disclosure of Positive BRCA1/2-Mutation Status in Young Couples: The Journey From Uncertainty to Bonding Through Partner Support. Fam Syst Health 2008;26:296-316. [PMID: 25132793 DOI: 10.1037/a0012914] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
29 Imai S, Ooki T, Murata-Kamiya N, Komura D, Tahmina K, Wu W, Takahashi-Kanemitsu A, Knight CT, Kunita A, Suzuki N, Del Valle AA, Tsuboi M, Hata M, Hayakawa Y, Ohnishi N, Ueda K, Fukayama M, Ushiku T, Ishikawa S, Hatakeyama M. Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis. Cell Host Microbe 2021;29:941-958.e10. [PMID: 33989515 DOI: 10.1016/j.chom.2021.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kim HS, Hwang IG, Min HY, Bang YJ, Kim WH. Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer. Oncol Lett 2019;17:4383-92. [PMID: 30988810 DOI: 10.3892/ol.2019.10132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Rocha FG. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:1400-6. [PMID: 33386541 DOI: 10.1245/s10434-020-09367-9] [Reference Citation Analysis]
32 Alkassis S, Yazdanpanah O, Philip PA. BRCA mutations in pancreatic cancer and progress in their targeting. Expert Opin Ther Targets 2021;25:547-57. [PMID: 34289788 DOI: 10.1080/14728222.2021.1957462] [Reference Citation Analysis]
33 Offit K. BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 2006;98:1675-7. [PMID: 17148764 DOI: 10.1093/jnci/djj500] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
34 Manders P, Pijpe A, Hooning MJ, Kluijt I, Vasen HFA, Hoogerbrugge N, van Asperen CJ, Meijers-heijboer H, Ausems MGEM, van Os TA, Gomez-garcia EB, Brohet RM, van Leeuwen FE, Rookus MA; HEBON. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat 2011;126:193-202. [DOI: 10.1007/s10549-010-1120-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
35 Kerger BD, James RC, Galbraith DA. Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry? Front Genet 2014;5:151. [PMID: 24910640 DOI: 10.3389/fgene.2014.00151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
36 Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26:5284-5293. [PMID: 18854563 DOI: 10.1200/jco.2008.18.1107] [Cited by in Crossref: 276] [Cited by in F6Publishing: 138] [Article Influence: 21.2] [Reference Citation Analysis]
37 Crum CP, Xian W. Bringing the p53 signature into focus. Cancer 2010;116:5119-21. [PMID: 20683929 DOI: 10.1002/cncr.25450] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
38 Delaloge S, Marsiglia H. Bases génétiques de la radiosensibilité des cancers du sein. Cancer/Radiothérapie 2005;9:77-86. [DOI: 10.1016/j.canrad.2004.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D’Adamo DR, Salo-Mullen E, Robson ME, Allen PJ. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16:1397-1402. [PMID: 21934105 DOI: 10.1634/theoncologist.2011-0185] [Cited by in Crossref: 159] [Cited by in F6Publishing: 121] [Article Influence: 15.9] [Reference Citation Analysis]
40 Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Pamula-Pilat J, Tecza K, Pekala W, Rembowska J, Nowicka K, Mosor M, Januszkiewicz-Lewandowska D, Rachtan J, Grzybowska E, Nowak J, Steffen J, Limon J. Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 2011;52:325-30. [PMID: 21503673 DOI: 10.1007/s13353-011-0040-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
41 Shiloh S, Dagan E, Friedman I, Blank N, Friedman E. A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes: Men tested for BRCA1/BRCA2 mutations. Psycho-Oncology 2011. [DOI: 10.1002/pon.2106] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
42 Kenen RH, Shapiro PJ, Hantsoo L, Friedman S, Coyne JC. Women with BRCA1 or BRCA2 mutations renegotiating a post-prophylactic mastectomy identity: self-image and self-disclosure. J Genet Couns 2007;16:789-98. [PMID: 17917796 DOI: 10.1007/s10897-007-9112-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
43 Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. BRCA1 and BRCA2 families and the risk of skin cancer. Fam Cancer 2010;9:489-93. [PMID: 20809262 DOI: 10.1007/s10689-010-9377-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
44 Macedo GS, Alemar B, Ashton-Prolla P. Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genet Mol Biol 2019;42:215-31. [PMID: 31067289 DOI: 10.1590/1678-4685-GMB-2018-0104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
45 Bruno M, Digennaro M, Tommasi S, Stea B, Danese T, Schittulli F, Paradiso A. Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women. Eur J Cancer Care (Engl) 2010;19:360-8. [PMID: 19912305 DOI: 10.1111/j.1365-2354.2009.01067.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
46 Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 2012;205:1-11. [PMID: 22429592 DOI: 10.1016/j.cancergen.2012.01.009] [Cited by in Crossref: 115] [Cited by in F6Publishing: 67] [Article Influence: 12.8] [Reference Citation Analysis]
47 Pasanisi P, Bruno E, Venturelli E, Manoukian S, Barile M, Peissel B, De Giacomi C, Bonanni B, Berrino J, Berrino F. Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. Fam Cancer 2011;10:521-8. [PMID: 21455766 DOI: 10.1007/s10689-011-9437-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
48 Mahfoudh W, Bouaouina N, Ahmed SB, Gabbouj S, Shan J, Mathew R, Uhrhammer N, Bignon YJ, Troudi W, Elgaaied AB, Hassen E, Chouchane L. Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep 2012;39:1037-46. [PMID: 21603858 DOI: 10.1007/s11033-011-0829-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
49 Jang AI, Bernstock JD, Segar DJ, Distasio M, Matulonis U, Bi WL. Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma. Front Surg 2021;8:594570. [PMID: 33681280 DOI: 10.3389/fsurg.2021.594570] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Rubinstein WS. Hereditary breast cancer in Jews. Familial Cancer 2004;3:249-57. [DOI: 10.1007/s10689-004-9550-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
51 Pande M, Joon A, Brewster AM, Chen WV, Hopper JL, Eng C, Shete S, Casey G, Schumacher F, Lin Y, Harrison TA, White E, Ahsan H, Andrulis IL, Whittemore AS, John EM, Ko Win A, Makalic E, Schmidt DF, Kapuscinski MK, Ochs-Balcom HM, Gallinger S, Jenkins MA, Newcomb PA, Lindor NM, Peters U, Amos CI, Lynch PM. Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS One 2018;13:e0196245. [PMID: 29698419 DOI: 10.1371/journal.pone.0196245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
52 Alli E, Solow-Cordero D, Casey SC, Ford JM. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res 2014;74:6205-15. [PMID: 25217519 DOI: 10.1158/0008-5472.CAN-14-1716] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
53 Girardstein-Boccara L, Mari V, Met-Domestici M, Burel-Vandenbos F, Berthet P, Paquis P, Frenay MP, Lebrun-Frenay C. [Gliomas and BRCA genes mutations: fortuitous association or imputability?]. Bull Cancer 2014;101:795-802. [PMID: 25295380 DOI: 10.1684/bdc.2014.1952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
54 Cannistrà M, Ruggiero M, Zullo A, Serafini S, Grande R, Nardo B. Metastases of pancreatic adenocarcinoma: A systematic review of literature and a new functional concept. Int J Surg 2015;21 Suppl 1:S15-21. [PMID: 26123383 DOI: 10.1016/j.ijsu.2015.04.093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
55 Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008;26:5530-6. [PMID: 18955455 DOI: 10.1200/JCO.2008.16.1703] [Cited by in Crossref: 305] [Cited by in F6Publishing: 131] [Article Influence: 23.5] [Reference Citation Analysis]
56 Cortesi L, Domati F, Guida A, Marchi I, Toss A, Barbieri E, Marcheselli L, Venturelli M, Piana S, Cirilli C, Federico M. BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees. Cancer Biol Med 2021:j. [PMID: 33710808 DOI: 10.20892/j.issn.2095-3941.2020.0481] [Reference Citation Analysis]
57 Riska A, Sund R, Pukkala E, Gissler M, Leminen A. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. Int J Cancer 2007;120:1351-4. [PMID: 17192898 DOI: 10.1002/ijc.22491] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
58 Brand R. Pancreatic cancer. Disease-a-Month 2004;50:545-55. [DOI: 10.1016/j.disamonth.2004.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
59 Hemminki K, Försti A, Lorenzo Bermejo J. Etiologic impact of known cancer susceptibility genes. Mutat Res 2008;658:42-54. [PMID: 17827054 DOI: 10.1016/j.mrrev.2007.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
60 Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers (Basel) 2021;13:1071. [PMID: 33802340 DOI: 10.3390/cancers13051071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Olivier RI, Lubsen-brandsma LA, van Boven H, van Beurden M. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? Gynecologic Oncology 2005;96:439-43. [DOI: 10.1016/j.ygyno.2004.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
62 Dann RB, Kelley JL, Zorn KK. Strategies for Ovarian Cancer Prevention. Obstetrics and Gynecology Clinics of North America 2007;34:667-86. [DOI: 10.1016/j.ogc.2007.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
63 Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:457-66. [PMID: 34337294 DOI: 10.1002/ags3.12436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Suchy J, Cybulski C, Górski B, Huzarski T, Byrski T, Dębniak T, Gronwald J, Jakubowska A, Wokołorczyk D, Kurzawski G, Kładny J, Jawień A, Banaszkiewicz Z, Wiśniowski R, Wandzel P, Starzewski J, Lorenc Z, Korobowicz E, Krokowicz P, Horbacka K, Lubiński J, Narod SA. BRCA1 mutations and colorectal cancer in Poland. Familial Cancer 2010;9:541-4. [DOI: 10.1007/s10689-010-9378-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
65 Miolo G, Puppa LD, Santarosa M, De Giacomi C, Veronesi A, Bidoli E, Tibiletti MG, Viel A, Dolcetti R. Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer 2006;6:156. [PMID: 16764716 DOI: 10.1186/1471-2407-6-156] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
66 Belogianni I, Apessos A, Mihalatos M, Razi E, Labropoulos S, Petounis A, Gaki V, Keramopoulos A, Pandis N, Kyriacou K, Hadjisavvas A, Kosmidis P, Yannoukakos D, Nasioulas G. Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer. BMC Cancer 2004;4:61. [PMID: 15353005 DOI: 10.1186/1471-2407-4-61] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
67 Llach J, Moreno L, Sánchez A, Herrera-Pariente C, Ocaña T, Cuatrecasas M, Rivero-Sánchez L, Moreira R, Díaz M, Jung G, Pellisé M, Castells A, Balaguer F, Carballal S, Moreira L. Genetic Counseling for Hereditary Gastric and Pancreatic Cancer in High-Risk Gastrointestinal Cancer Clinics: An Effective Strategy. Cancers (Basel) 2020;12:E2386. [PMID: 32842532 DOI: 10.3390/cancers12092386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
68 Ali-Fehmi R, Chatterjee M, Ionan A, Levin NK, Arabi H, Bandyopadhyay S, Shah JP, Bryant CS, Hewitt SM, O'Rand MG, Alekseev OM, Morris R, Munkarah A, Abrams J, Tainsky MA. Analysis of the expression of human tumor antigens in ovarian cancer tissues. Cancer Biomark 2010;6:33-48. [PMID: 20164540 DOI: 10.3233/CBM-2009-0117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
69 Upton DH, Fuller ES, Colvin EK, Walters KA, Jimenez M, Desai R, Handelsman DJ, Howell VM, Allan CM. Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors. Horm Cancer 2015;6:142-52. [PMID: 25943777 DOI: 10.1007/s12672-015-0222-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Fabian CJ, Kimler BF. Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer. JCO 2005;23:1644-55. [DOI: 10.1200/jco.2005.11.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
71 Sharma MB, Carus A, Sunde L, Hamilton-dutoit S, Ladekarl M. BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping. Acta Oncologica 2016;55:377-81. [DOI: 10.3109/0284186x.2015.1044023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
72 Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306:1557-1565. [PMID: 21990299 DOI: 10.1001/jama.2011.1456] [Cited by in Crossref: 333] [Cited by in F6Publishing: 277] [Article Influence: 33.3] [Reference Citation Analysis]
73 Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst. 2004;96:68-70. [PMID: 14709740 DOI: 10.1093/jnci/djh006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
74 Engel C, Fischer C. Breast cancer risks and risk prediction models. Breast Care (Basel) 2015;10:7-12. [PMID: 25960719 DOI: 10.1159/000376600] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
75 Korde LA, Calzone KA, Zujewski J. Assessing breast cancer risk: Genetic factors are not the whole story. Postgraduate Medicine 2015;116:6-34. [DOI: 10.3810/pgm.2004.10.1595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
76 Hughes DJ. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam Cancer 2008;7:233-44. [PMID: 18283561 DOI: 10.1007/s10689-008-9181-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
77 Cavanagh H, Rogers KM. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015;13:16. [PMID: 26236408 DOI: 10.1186/s13053-015-0038-x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 11.2] [Reference Citation Analysis]
78 Dowdy SC, Stefanek M, Hartmann LC. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol. 2004;191:1113-1123. [PMID: 15507929 DOI: 10.1016/j.ajog.2004.04.028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
79 Naseem H, Boylan J, Speake D, Leask K, Shenton A, Lalloo F, Hill J, Trump D, Evans DG. Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes. Clin Genet 2006;70:388-95. [PMID: 17026620 DOI: 10.1111/j.1399-0004.2006.00698.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
80 Loos M, Michalski CW, Kleeff J. Asymptomatic pancreatic lesions: new insights and clinical implications. World J Gastroenterol 2012;18:4474-7. [PMID: 22969218 DOI: 10.3748/wjg.v18.i33.4474] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Rego SM, Snyder MP. High Throughput Sequencing and Assessing Disease Risk. Cold Spring Harb Perspect Med 2019;9:a026849. [PMID: 29959131 DOI: 10.1101/cshperspect.a026849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
82 Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 2007;44:467-71. [PMID: 17307836 DOI: 10.1136/jmg.2006.048173] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
83 Lynch HT, Deters CA, Snyder CL, Lynch JF, Villeneuve P, Silberstein J, Martin H, Narod SA, Brand RE. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet. 2005;158:119-125. [PMID: 15796958 DOI: 10.1016/j.cancergencyto.2004.01.032] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
84 Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I. BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018;110:1178-1189. [PMID: 30380096 DOI: 10.1093/jnci/djy148] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 22.0] [Reference Citation Analysis]
85 Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003;21:593-601. [PMID: 12586794 DOI: 10.1200/JCO.2003.07.007] [Cited by in Crossref: 125] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
86 Laraqui A, Uhrhammer N, Lahlou-Amine I, El Rhaffouli H, El Baghdadi J, Dehayni M, Moussaoui RD, Ichou M, Sbitti Y, Al Bouzidi A, Amzazi S, Bignon YJ. Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci 2013;10:60-7. [PMID: 23289006 DOI: 10.7150/ijms.5014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
87 Cheng Q, Bilgin CC, Fontenay G, Chang H, Henderson M, Han J, Parvin B. Stiffness of the microenvironment upregulates ERBB2 expression in 3D cultures of MCF10A within the range of mammographic density. Sci Rep 2016;6:28987. [PMID: 27383056 DOI: 10.1038/srep28987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
88 Berrino J, Berrino F, Francisci S, Peissel B, Azzollini J, Pensotti V, Radice P, Pasanisi P, Manoukian S. Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Fam Cancer 2015;14:117-28. [PMID: 25373702 DOI: 10.1007/s10689-014-9766-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
89 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
90 Axilbund JE, Wiley EA. Genetic testing by cancer site: pancreas. Cancer J 2012;18:350-4. [PMID: 22846737 DOI: 10.1097/PPO.0b013e3182624694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
91 Laporte GA, Leguisamo NM, Kalil AN, Saffi J. Clinical importance of DNA repair in sporadic colorectal cancer. Crit Rev Oncol Hematol 2018;126:168-85. [PMID: 29759559 DOI: 10.1016/j.critrevonc.2018.03.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
92 Simeone AM, Deng CX, Kelloff GJ, Steele VE, Johnson MM, Tari AM. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 2005;26:1000-7. [PMID: 15695235 DOI: 10.1093/carcin/bgi038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
93 Wong A, Ngeow J. Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment? Biomed Res Int 2015;2015:219012. [PMID: 26161390 DOI: 10.1155/2015/219012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
94 Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G. Male Breast Cancer in Togo: Imaging and Clinicopathological Findings. Int J Breast Cancer 2020;2020:3056067. [PMID: 32934847 DOI: 10.1155/2020/3056067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Flippo-morton T, Walsh K, Chambers K, Amacker-north L, White B, Sarantou T, Boselli DM, White RL. Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature. Breast J 2016;22:35-44. [DOI: 10.1111/tbj.12521] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
96 Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055-1062. [PMID: 14981104 DOI: 10.1200/jco.2004.04.188] [Cited by in Crossref: 769] [Cited by in F6Publishing: 192] [Article Influence: 45.2] [Reference Citation Analysis]
97 Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008-2020. [PMID: 32593337 DOI: 10.1016/S0140-6736(20)30974-0] [Cited by in Crossref: 142] [Cited by in F6Publishing: 40] [Article Influence: 142.0] [Reference Citation Analysis]
98 Landsbergen KM, Prins JB, Kamm YJ, Brunner HG, Hoogerbrugge N. Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years. Fam Cancer 2010;9:213-20. [PMID: 19967456 DOI: 10.1007/s10689-009-9311-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
99 Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S. Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. Breast Cancer Res Treat 2017;162:225-30. [DOI: 10.1007/s10549-017-4122-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
100 Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, Wacholder S. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS One 2009;4:e4812. [PMID: 19277124 DOI: 10.1371/journal.pone.0004812] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
101 Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Noguès C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R. [Identification and management of hereditary breast-ovarian cancers (2004 update)]. Pathol Biol (Paris) 2006;54:230-50. [PMID: 16632260 DOI: 10.1016/j.patbio.2006.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
102 Russo A, Calò V, Agnese V, Bruno L, Corsale S, Augello C, Gargano G, Barbera F, Cascio S, Intrivici C, Rinaldi G, Gulotta G, Macaluso M, Surmacz E, Giordano A, Gebbia N, Bazan V. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses. Breast Cancer Res Treat 2007;105:267-76. [PMID: 17221156 DOI: 10.1007/s10549-006-9456-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
103 Saldia A, Olson SH, Nunes P, Liang X, Samson ML, Salo-Mullen E, Marcell V, Stadler ZK, Allen PJ, Offit K, Kurtz RC. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Cancer Prev Res (Phila) 2019;12:599-608. [PMID: 31337648 DOI: 10.1158/1940-6207.CAPR-18-0272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Greer JB, Lynch HT, Brand RE. Hereditary pancreatic cancer: a clinical perspective. Best Pract Res Clin Gastroenterol. 2009;23:159-170. [PMID: 19414143 DOI: 10.1016/j.bpg.2009.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
105 Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivanco G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract 2017;15:9. [PMID: 28670351 DOI: 10.1186/s13053-017-0069-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
106 Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006;24:4642-4660. [PMID: 17008706 DOI: 10.1200/jco.2005.04.5260] [Cited by in Crossref: 158] [Cited by in F6Publishing: 33] [Article Influence: 10.5] [Reference Citation Analysis]
107 Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int 2015;2015:341723. [PMID: 26075229 DOI: 10.1155/2015/341723] [Cited by in Crossref: 84] [Cited by in F6Publishing: 50] [Article Influence: 14.0] [Reference Citation Analysis]
108 Lami G, Biagini MR, Galli A. Endoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancer. World J Gastrointest Endosc. 2014;6:272-285. [PMID: 25031786 DOI: 10.4253/wjge.v6.i7.272] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
109 Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22:735-42. [PMID: 14966099 DOI: 10.1200/JCO.2004.05.055] [Cited by in Crossref: 269] [Cited by in F6Publishing: 86] [Article Influence: 15.8] [Reference Citation Analysis]
110 Eoh KJ, Kim JE, Park HS, Lee ST, Park JS, Han JW, Lee JY, Kim S, Kim SW, Kim JH, Kim YT, Nam EJ. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2. Cancer Res Treat 2018;50:917-25. [PMID: 29020732 DOI: 10.4143/crt.2017.220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
111 Morgan D, Sylvester H, Lucas FL, Miesfeldt S. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 2009;8:277-87. [PMID: 19347608 DOI: 10.1007/s10689-009-9242-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
112 Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health 2010;10:28. [PMID: 20961453 DOI: 10.1186/1472-6874-10-28] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
113 Yang Y, Hong C, Liang JW, Gruber S, Parmigiani G, Idos G, Braun D. A likelihood-based approach to assessing frequency of pathogenicity among variants of unknown significance in susceptibility genes. Stat Med 2021;40:593-606. [PMID: 33120437 DOI: 10.1002/sim.8791] [Reference Citation Analysis]
114 Sereno M, Aguayo C, Guillén Ponce C, Gómez-Raposo C, Zambrana F, Gómez-López M, Casado E. Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention. Clin Transl Oncol. 2011;13:599-610. [PMID: 21865131 DOI: 10.1007/s12094-011-0705-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
115 Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci 2009;34:415-22. [PMID: 19805903 DOI: 10.1007/s12038-009-0048-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
116 Jiang Y, Tian T, Yu C, Zhou W, Yang J, Wang Y, Wen Y, Chen J, Dai J, Jin G, Ma H, Shen H, Hu Z. Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population. Biomed Res Int 2020;2020:6739823. [PMID: 32879886 DOI: 10.1155/2020/6739823] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Douglas JA, Levin AM, Zuhlke KA, Ray AM, Johnson GR, Lange EM, Wood DP, Cooney KA. Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:1510-1516. [PMID: 17585057 DOI: 10.1158/1055-9965.epi-07-0137] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
118 Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010; 139: 1076-1080, 1080.e1-1080. e2. [PMID: 20727885 DOI: 10.1053/j.gastro.2010.08.012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
119 Loman N, Bladström A, Johannsson O, Borg A, Olsson H. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 2003;5:R175-86. [PMID: 14580253 DOI: 10.1186/bcr632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
120 Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014;20:11182-11198. [PMID: 25170203 DOI: 10.3748/wjg.v20.i32.11182] [Cited by in CrossRef: 156] [Cited by in F6Publishing: 127] [Article Influence: 26.0] [Reference Citation Analysis]
121 DiFeo A, Narla G, Martignetti JA. Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. Mt Sinai J Med 2009;76:557-66. [PMID: 20014424 DOI: 10.1002/msj.20150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
122 Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL. Identification of germline 185delAGBRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 2003;98:597-602. [DOI: 10.1002/cncr.11533] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
123 Gatenby RA, Brown J. Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. Biochim Biophys Acta Rev Cancer. 2017;1867:162-166. [PMID: 28341421 DOI: 10.1016/j.bbcan.2017.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
124 Vadaparampil ST, Quinn GP, Knapp C, Malo TL, Friedman S. Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer. Genet Med. 2009;11:757-765. [PMID: 19710615 DOI: 10.1097/gim.0b013e3181b3f451] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
125 Curtin NJ. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol 2013;169:1745-65. [PMID: 23682925 DOI: 10.1111/bph.12244] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
126 Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Rev Anticancer Ther 2015;15:1223-31. [PMID: 26402249 DOI: 10.1586/14737140.2015.1086271] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
127 Leoz ML, Sánchez A, Carballal S, Ruano L, Ocaña T, Pellisé M, Castells A, Balaguer F, Moreira L. Hereditary gastric and pancreatic cancer predisposition syndromes. Gastroenterología y Hepatología (English Edition) 2016;39:481-93. [DOI: 10.1016/j.gastre.2016.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
128 Meattini I, Livi L, Franceschini D, Saieva C, Scotti V, Casella D, Criscenti V, Zanna I, Meacci F, Gerlain E, Agresti B, Mangoni M, Paiar F, Simontacchi G, Greto D, Nori J, Bianchi S, Cataliotti L, Biti G. Treatment of invasive male breast cancer: a 40-year single-institution experience. Radiol Med 2013;118:476-86. [PMID: 22872459 DOI: 10.1007/s11547-012-0867-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
129 Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-salamanca MB, Carballo-rastrilla S, Cádenas-rebollo JM, García-garcia A, Gil-ibáñez B, Juan-fita MJ, Patrono MG. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. Clin Transl Oncol 2018;20:1337-44. [DOI: 10.1007/s12094-018-1865-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
130 Karlan BY. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecologic Oncology 2004;92:519-20. [DOI: 10.1016/j.ygyno.2003.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
131 Leoz ML, Sánchez A, Carballal S, Ruano L, Ocaña T, Pellisé M, Castells A, Balaguer F, Moreira L. [Hereditary gastric and pancreatic cancer predisposition syndromes]. Gastroenterol Hepatol 2016;39:481-93. [PMID: 26916701 DOI: 10.1016/j.gastrohep.2015.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
132 Overbeek KA, Cahen DL, Canto MI, Bruno MJ. Surveillance for neoplasia in the pancreas. Best Pract Res Clin Gastroenterol 2016;30:971-86. [PMID: 27938791 DOI: 10.1016/j.bpg.2016.10.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
133 Russo A, Calò V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol 2009;69:28-44. [PMID: 18656380 DOI: 10.1016/j.critrevonc.2008.06.003] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
134 Connor AA, Gallinger S. Hereditary Pancreatic Cancer Syndromes. Surg Oncol Clin N Am. 2015;24:733-764. [PMID: 26363539 DOI: 10.1016/j.soc.2015.06.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
135 Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol 2006;2:257-74. [PMID: 16563094 DOI: 10.2217/14796694.2.2.257] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
136 Hirt R, Davy C, Guibert J, Olivennes F. Pregnancy after in vitro fertilization-intracytoplasmic sperm injection obtained with a modified natural cycle in a BRCA1 mutation carrier. Fertil Steril 2008;90:1199.e25-8. [PMID: 18155199 DOI: 10.1016/j.fertnstert.2007.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
137 Robles-d�az L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer 2004;3:259-64. [DOI: 10.1007/s10689-004-9552-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
138 Khan MH, Allerton R, Pettit L. Hormone Therapy for Breast Cancer in Men. Clin Breast Cancer 2015;15:245-50. [PMID: 26165199 DOI: 10.1016/j.clbc.2015.01.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
139 Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McLennan J, Sun P, Narod SA. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005;96:222-6. [PMID: 15589605 DOI: 10.1016/j.ygyno.2004.09.039] [Cited by in Crossref: 104] [Cited by in F6Publishing: 79] [Article Influence: 6.5] [Reference Citation Analysis]
140 Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941-3. [PMID: 12464584 DOI: 10.1007/BF02574510] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
141 Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012;118:3703-9. [PMID: 22139894 DOI: 10.1002/cncr.26655] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
142 Mocci E, Milne RL, Méndez-Villamil EY, Hopper JL, John EM, Andrulis IL, Chung WK, Daly M, Buys SS, Malats N, Goldgar DE. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev 2013;22:803-11. [PMID: 23456555 DOI: 10.1158/1055-9965.EPI-12-0195] [Cited by in Crossref: 56] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
143 Leunen K, Legius E, Moerman P, Amant F, Neven P, Vergote I. Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. Int J Gynecol Cancer 2006;16:183-8. [DOI: 10.1111/j.1525-1438.2006.00287.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
144 Riska A, Pukkala E, Scélo G, Mellemkjaer L, Hemminki K, Weiderpass E, Mcbride ML, Pompe-kirn V, Tracey E, Brewster DH, Kliewer EV, Tonita JM, Kee-seng C, Jonasson JG, Martos C, Boffetta P, Brennan P. Second primary malignancies in females with primary fallopian tube cancer. Int J Cancer 2007;120:2047-51. [DOI: 10.1002/ijc.22562] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
145 Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009;3:97-137. [PMID: 19383374 DOI: 10.1016/j.molonc.2009.02.004] [Cited by in Crossref: 121] [Cited by in F6Publishing: 82] [Article Influence: 10.1] [Reference Citation Analysis]
146 Agnantis NJ, Paraskevaidis E, Roukos D. Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance. Ann Surg Oncol 2004;11:1030-4. [DOI: 10.1245/aso.2004.09.910] [Cited by in Crossref: 66] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
147 Mota A, S Oltra S, Moreno-Bueno G. Insight updating of the molecular hallmarks in ovarian carcinoma. EJC Suppl 2020;15:16-26. [PMID: 33240439 DOI: 10.1016/j.ejcsup.2019.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Randall LM, Pothuri B. The genetic prediction of risk for gynecologic cancers. Gynecol Oncol 2016;141:10-6. [PMID: 27016223 DOI: 10.1016/j.ygyno.2016.03.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
149 Ballinger LL. Hereditary Gynecologic Cancers. Obstetrics and Gynecology Clinics of North America 2012;39:165-81. [DOI: 10.1016/j.ogc.2012.02.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
150 Dubeau L. Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications. Transl Cancer Res 2015;4:3-13. [PMID: 26568913 DOI: 10.3978/j.issn.2218-676X.2015.01.06] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
151 Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010;12:245-59. [PMID: 20216074 DOI: 10.1097/GIM.0b013e3181d38f2f] [Cited by in Crossref: 176] [Cited by in F6Publishing: 94] [Article Influence: 16.0] [Reference Citation Analysis]
152 Axilbund JE, Argani P, Kamiyama M, Palmisano E, Raben M, Borges M, Brune KA, Goggins M, Hruban RH, Klein AP. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther 2009;8:131-5. [PMID: 19029836 DOI: 10.4161/cbt.8.2.7136] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
153 Donner I, Katainen R, Sipilä LJ, Aavikko M, Pukkala E, Aaltonen LA. Germline mutations in young non-smoking women with lung adenocarcinoma. Lung Cancer 2018;122:76-82. [DOI: 10.1016/j.lungcan.2018.05.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
154 Ren X, Yan T, Zhang S, Zhang X, Gao P, Wu D, Du B, Wei Q. Ultrasensitive dual amplification sandwich immunosensor for breast cancer susceptibility gene based on sheet materials. Analyst 2014;139:3061-8. [DOI: 10.1039/c4an00099d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
155 Hermsen BB, van Diest PJ, Berkhof J, Menko FH, Gille JJ, Piek JM, Meijer S, Winters HA, Kenemans P, Mensdorff-pouilly SV, Verheijen RH. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 2006;119:1412-8. [DOI: 10.1002/ijc.21988] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
156 Quinn GP, Vadaparampil ST, Miree CA, Lee JH, Zhao X, Friedman S, Yi S, Mayer J. High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer. Hum Reprod 2010;25:2543-50. [PMID: 20713415 DOI: 10.1093/humrep/deq207] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
157 Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007;43:238-57. [PMID: 17095205 DOI: 10.1016/j.ejca.2006.07.019] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
158 Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009;133:365-374. [PMID: 19260742 DOI: 10.5858/133.3.365] [Cited by in Crossref: 17] [Cited by in F6Publishing: 68] [Article Influence: 1.4] [Reference Citation Analysis]
159 Calip GS, Kidd J, Bernhisel R, Cox HC, Saam J, Rauscher GH, Lancaster JM, Hoskins KF. Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling. Breast Cancer Res Treat 2021;185:195-204. [PMID: 32918117 DOI: 10.1007/s10549-020-05922-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
160 Llach J, Carballal S, Moreira L. Familial Pancreatic Cancer: Current Perspectives. Cancer Manag Res 2020;12:743-58. [PMID: 32099470 DOI: 10.2147/CMAR.S172421] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
161 Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22. [PMID: 23628597 DOI: 10.1093/jnci/djt095] [Cited by in Crossref: 548] [Cited by in F6Publishing: 369] [Article Influence: 68.5] [Reference Citation Analysis]
162 Ji J, Hemminki K. Second gastric cancers among patients with primary sporadic and familial cancers in Sweden. Gut 2006;55:896-8. [PMID: 16698758 DOI: 10.1136/gut.2005.090118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
163 Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol. 2006;13:1296-1321. [PMID: 16990987 DOI: 10.1245/s10434-006-9036-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
164 Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 2008;110:99-109. [PMID: 17851763 DOI: 10.1007/s10549-007-9708-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 5.1] [Reference Citation Analysis]
165 Lim D, Ngeow J. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. Endocrine-Related Cancer 2016;23:R267-85. [DOI: 10.1530/erc-16-0116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
166 Cohn WF, Jones SM, Miesfeldt S. "Are you at risk for hereditary breast cancer?": development of a personal risk assessment tool for hereditary breast and ovarian cancer. J Genet Couns 2008;17:64-78. [PMID: 18181014 DOI: 10.1007/s10897-007-9125-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
167 O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol. 2014;4:42. [PMID: 24616882 DOI: 10.3389/fonc.2014.00042] [Cited by in Crossref: 35] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
168 Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA Carrier Probabilities in Extended Families. JCO 2006;24:354-60. [DOI: 10.1200/jco.2005.02.2368] [Cited by in Crossref: 68] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
169 Torphy RJ, Schulick RD. Screening of Patients at Risk for Familial Pancreatic Cancer. Surgical Clinics of North America 2018;98:25-35. [DOI: 10.1016/j.suc.2017.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
170 de Juan I, Esteban E, Palanca S, Barragán E, Bolufer P. High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations. Breast Cancer Res Treat 2009;115:405-14. [PMID: 18528753 DOI: 10.1007/s10549-008-0073-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
171 Weeden CE, Asselin-Labat ML. Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. Biochim Biophys Acta Mol Basis Dis 2018;1864:89-101. [PMID: 29038050 DOI: 10.1016/j.bbadis.2017.10.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
172 Hopper J, Jenkins M, Dowty J, Dite G, Apicella C, Keogh L, Win A, Young J, Buchanan D, Walsh M, Rosty C, Baglietto L, Severi G, Phillips K, Wong E, Dobrovic A, Waring P, Winship I, Ramus S, Giles G, Southey M. Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers. Pathology 2012;44:89-98. [DOI: 10.1097/pat.0b013e32834e8e5b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
173 Yun EJ, Lin CJ, Dang A, Hernandez E, Guo J, Chen WM, Allison J, Kim N, Kapur P, Brugarolas J, Wu K, He D, Lai CH, Lin H, Saha D, Baek ST, Chen BPC, Hsieh JT. Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. Clin Cancer Res 2019;25:4542-51. [PMID: 31000589 DOI: 10.1158/1078-0432.CCR-18-3004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
174 Vaz FH, Machado PM, Brandão RD, Laranjeira CT, Eugénio JS, Fernandes AH, André SP. Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients. J Histochem Cytochem 2007;55:1105-13. [PMID: 17625228 DOI: 10.1369/jhc.7A7209.2007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
175 Teller P, Kramer RK. Management of the asymptomatic BRCA mutation carrier. Appl Clin Genet. 2010;3:121-131. [PMID: 23776357 DOI: 10.2147/tacg.s8882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
176 Haddad A, Kowdley GC, Pawlik TM, Cunningham SC. Hereditary pancreatic and hepatobiliary cancers. Int J Surg Oncol 2011;2011:154673. [PMID: 22312493 DOI: 10.1155/2011/154673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
177 Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, Hilali F, El Baghdadi J, Al Bouzidi A, Bakri Y, Amzazi S, Bignon YJ. BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African. Dis Markers 2015;2015:194293. [PMID: 25814778 DOI: 10.1155/2015/194293] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
178 Daley D, Lewis S, Platzer P, MacMillen M, Willis J, Elston RC, Markowitz SD, Wiesner GL. Identification of susceptibility genes for cancer in a genome-wide scan: results from the colon neoplasia sibling study. Am J Hum Genet 2008;82:723-36. [PMID: 18313025 DOI: 10.1016/j.ajhg.2008.01.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
179 Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat 2015;154:441-53. [PMID: 26564481 DOI: 10.1007/s10549-015-3629-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
180 Kroiss R, Winkler V, Bikas D, Fleischmann E, Mainau C, Frommlet F, Muhr D, Fuerhauser C, Tea M, Bittner B, Kubista E, Oefner PJ, Bauer P, Wagner TM; Austrian Hereditary Breast and Ovarian Cancer Group. Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers. Hum Mutat 2005;26:583-9. [PMID: 16287141 DOI: 10.1002/humu.20261] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
181 Dutil J, Colon-Colon JL, Matta JL, Sutphen R, Echenique M. Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genet 2012;205:242-8. [PMID: 22682623 DOI: 10.1016/j.cancergen.2012.04.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
182 Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD. Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians. JCO 2003;21:4322-8. [DOI: 10.1200/jco.2003.02.107] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
183 Whitcomb D, Greer J. Germ-line mutations, pancreatic inflammation, and pancreatic cancer. Clin Gastroenterol Hepatol. 2009;7:S29-S34. [PMID: 19896094 DOI: 10.1016/j.cgh.2009.07.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
184 Xu Y, Li C, Wang Z, Liu F, Xu Y. Comparison of suspected Lynch syndrome patients carrying BRCA and BRCA-like variants with Lynch syndrome probands: Phenotypic characteristics and pedigree analyses. Mol Genet Genomic Med. 2020;8:e1359. [PMID: 32548945 DOI: 10.1002/mgg3.1359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Lorenzo Bermejo J, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol. 2004;15:1834-1841. [PMID: 15550590 DOI: 10.1093/annonc/mdh474] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
186 Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World J Clin Oncol 2020;11:868-89. [PMID: 33312883 DOI: 10.5306/wjco.v11.i11.868] [Reference Citation Analysis]
187 Deng W, Jin L, Zhuo H, Vasiliou V, Zhang Y. Alcohol consumption and risk of stomach cancer: A meta-analysis. Chem Biol Interact 2021;336:109365. [PMID: 33412155 DOI: 10.1016/j.cbi.2021.109365] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Garber JE, Syngal S. One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers. J Natl Cancer Inst 2004;96:2-3. [PMID: 14709725 DOI: 10.1093/jnci/djh021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
189 Clark AS, Domchek SM. Clinical Management of Hereditary Breast Cancer Syndromes. J Mammary Gland Biol Neoplasia 2011;16:17-25. [DOI: 10.1007/s10911-011-9200-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
190 Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015;121:4382-4388. [PMID: 26440929 DOI: 10.1002/cncr.29664] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 17.2] [Reference Citation Analysis]
191 Wang L, Di LJ. BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact? Int J Biol Sci 2014;10:566-75. [PMID: 24910535 DOI: 10.7150/ijbs.8579] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
192 Vos JR, Hsu L, Brohet RM, Mourits MJ, de Vries J, Malone KE, Oosterwijk JC, de Bock GH. Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol 2015;33:2553-62. [PMID: 26150446 DOI: 10.1200/JCO.2014.59.0463] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
193 Pichert G, Jacobs C, Jacobs I, Menon U, Manchanda R, Johnson M, Hamed H, Firth C, Evison M, Tutt A, de Silva L, Langman C, Izatt L. Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Fam Cancer 2010;9:313-9. [PMID: 20300867 DOI: 10.1007/s10689-010-9333-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
194 Brachot-simeonova I, Morin G, Gillaux C, Demeer B, Gondry J, Mathieu M, Fauvet R. Quelle prise en charge pour les hommes asymptomatiques, porteurs d’une mutation du gène BRCA1 ou 2 ? Résultat d’une enquête de pratique auprès des centres d’oncogénétique français. Bulletin du Cancer 2012;99:417-23. [DOI: 10.1684/bdc.2012.1552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol 2016;34:1460-8. [PMID: 26976419 DOI: 10.1200/JCO.2015.65.0747] [Cited by in Crossref: 247] [Cited by in F6Publishing: 111] [Article Influence: 49.4] [Reference Citation Analysis]
196 Hoskins PJ, Gotlieb WH. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. CA Cancer J Clin 2017;67:493-506. [PMID: 28881380 DOI: 10.3322/caac.21408] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 9.8] [Reference Citation Analysis]
197 Ławniczak M, Jakubowska A, Białek A, Lubiński J, Jaworska-Bieniek K, Kaczmarek K, Starzyńska T. BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population. Hered Cancer Clin Pract 2016;14:3. [PMID: 26779294 DOI: 10.1186/s13053-015-0043-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
198 Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI;  Participants of the Fourth International Symposium of Inherited Diseases of the Pancreas. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007;56:1460-1469. [PMID: 17872573 DOI: 10.1136/gut.2006.108456] [Cited by in Crossref: 204] [Cited by in F6Publishing: 165] [Article Influence: 14.6] [Reference Citation Analysis]
199 Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J Cancer 2021;12:38-53. [PMID: 33391401 DOI: 10.7150/jca.49406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
200 Webb C. Whose body is it anyway? Nursing (Lond). 1991;4:9-11. [PMID: 1876298 DOI: 10.1007/s00439-008-0554-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
201 Jo WS, Chung DC. Genetics of hereditary colorectal cancer. Semin Oncol 2005;32:11-23. [PMID: 15726502 DOI: 10.1053/j.seminoncol.2004.09.034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
202 Kenen RH, Shapiro PJ, Friedman S, Coyne JC. Peer-support in coping with medical uncertainty: discussion of oophorectomy and hormone replacement therapy on a web-based message board. Psychooncology 2007;16:763-71. [PMID: 17230435 DOI: 10.1002/pon.1152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
203 Cerbinskaite A, Mukhopadhyay A, Plummer E, Curtin N, Edmondson R. Defective homologous recombination in human cancers. Cancer Treatment Reviews 2012;38:89-100. [DOI: 10.1016/j.ctrv.2011.04.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
204 Stoffel EM. Screening in GI Cancers: The Role of Genetics. J Clin Oncol. 2015;33:1721-1728. [PMID: 25918283 DOI: 10.1200/jco.2014.60.6764] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
205 Bradbury AR, Patrick-Miller L, Pawlowski K, Ibe CN, Cummings SA, Hlubocky F, Olopade OI, Daugherty CK. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology 2009;18:200-8. [PMID: 18702049 DOI: 10.1002/pon.1384] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
206 Williams CB, Soloff AC, Ethier SP, Yeh ES. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting. Adv Cancer Res 2015;127:253-81. [PMID: 26093903 DOI: 10.1016/bs.acr.2015.04.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
207 Lu SM, Waldman LE, Boudiab EM, Lopez CD, Bassiri-Tehrani B, DelMauro MA, Israeli R, Bank J, Machnicki SC, Lerman OZ. Incidence, Impact, and Management of Incidentalomas on Preoperative Computed Tomographic Angiograms for Breast Cancer Patients with and without Genetic Mutations. Plast Reconstr Surg 2021;147:1259-69. [PMID: 33974589 DOI: 10.1097/PRS.0000000000007941] [Reference Citation Analysis]
208 Rebbeck TR, Domchek SM. Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2008;10:108. [PMID: 18710587 DOI: 10.1186/bcr2115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
209 Brown AD, Claybon AB, Bishop AJ. A conditional mouse model for measuring the frequency of homologous recombination events in vivo in the absence of essential genes. Mol Cell Biol 2011;31:3593-602. [PMID: 21709021 DOI: 10.1128/MCB.00848-10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
210 Pilato B, De Summa S, Danza K, Lambo R, Paradiso A, Tommasi S. Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report. Breast Cancer Res Treat 2010;124:875-8. [DOI: 10.1007/s10549-010-1125-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
211 Humphris JL, Biankin AV. Diagnosis and Management of Hereditary Pancreatic Cancer. In: Pichert G, Jacobs C, editors. Rare Hereditary Cancers. Cham: Springer International Publishing; 2016. pp. 61-83. [DOI: 10.1007/978-3-319-29998-3_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
212 Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes.Cancer J. 2012;18:485-491. [PMID: 23187834 DOI: 10.1097/PPO.0b013e318278c4a6] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 7.6] [Reference Citation Analysis]
213 Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 2011;1815:44-64. [PMID: 20888394 DOI: 10.1016/j.bbcan.2010.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 52] [Article Influence: 1.9] [Reference Citation Analysis]
214 Pothuri B. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol 2013;24 Suppl 8:viii22-7. [PMID: 24131965 DOI: 10.1093/annonc/mdt307] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
215 Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C, Pike MC, Shuler CF, Maxson R, Dubeau L. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005;15:561-5. [PMID: 15797026 DOI: 10.1016/j.cub.2005.01.052] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
216 Boetes C. Update on screening breast MRI in high-risk women. Obstet Gynecol Clin North Am 2011;38:149-58, viii-ix. [PMID: 21419331 DOI: 10.1016/j.ogc.2011.02.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
217 Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, Gotlieb W, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, Provencher D, Mes-Masson AM. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecol Oncol 2020;156:377-86. [PMID: 31753525 DOI: 10.1016/j.ygyno.2019.11.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
218 Martin ES, Croce CM, Biggs DD, Martin SE. BRCA1 IVS2-2delA: a deleterious mutation in a family of Asian descent. Cancer Genet Cytogenet 2004;150:173-5. [PMID: 15066328 DOI: 10.1016/j.cancergencyto.2003.08.024] [Reference Citation Analysis]
219 Whitcomb DC, Shelton CA, Brand RE. Genetics and Genetic Testing in Pancreatic Cancer. Gastroenterology. 2015;149:1252-1264.e4. [PMID: 26255042 DOI: 10.1053/j.gastro.2015.07.057] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
220 Sopik V, Phelan C, Cybulski C, Narod S. BRCA1 and BRCA2 mutations and the risk for colorectal cancer: BRCA1 and colorectal cancer. Clin Genet 2015;87:411-8. [DOI: 10.1111/cge.12497] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
221 Heimdal K, Mæhle L, Apold J, Pedersen J, Møller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. European Journal of Cancer 2003;39:2205-13. [DOI: 10.1016/s0959-8049(03)00548-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
222 Drikos I, Nounesis G, Vorgias CE. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets. Proteins 2009;77:464-76. [PMID: 19452558 DOI: 10.1002/prot.22460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
223 Reynolds C, Davidson JA, Lindor NM, Glazebrook KN, Jakub JW, Degnim AC, Sandhu NP, Walsh MF, Hartmann LC, Boughey JC. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved? Ann Surg Oncol. 2011;18:3102-3109. [PMID: 21947588 DOI: 10.1245/s10434-011-1908-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
224 Rashid MU, Gull S, Faisal S, Khaliq S, Asghar K, Siddiqui N, Amin A, Hamann U. Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan. Fam Cancer 2011;10:709-12. [PMID: 21751003 DOI: 10.1007/s10689-011-9467-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
225 Steinberg WM, Barkin JS, Bradley EL 3rd, DiMagno E, Layer P, Canto MI, Levy MJ. Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas? Pancreas. 2009;38:e137-e150. [PMID: 19550273 DOI: 10.1097/mpa.0b013e3181a86b2c] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
226 Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Suen DT, Choi C, Ho LS, Kwan KH, Poon M, Wong TT, Chan K, Chan SW, Ying MW, Chan WC, Ma ES, Ford JM, West DW. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J 2009;3:63-76. [PMID: 20535403 DOI: 10.1007/s11568-010-9136-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
227 Mills K, Fuh K. Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Res 2017;6:84. [PMID: 28184293 DOI: 10.12688/f1000research.9977.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
228 Tung N, Silver DP. Chek2 DNA damage response pathway and inherited breast cancer risk. J Clin Oncol 2011;29:3813-5. [PMID: 21876079 DOI: 10.1200/JCO.2011.37.1476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
229 Ben Ayed-Guerfali D, Ben Kridis-Rejab W, Ammous-Boukhris N, Ayadi W, Charfi S, Khanfir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. J Transl Med 2021;19:108. [PMID: 33726785 DOI: 10.1186/s12967-021-02772-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010;16:2115-21. [PMID: 20215531 DOI: 10.1158/1078-0432.CCR-09-2871] [Cited by in Crossref: 167] [Cited by in F6Publishing: 74] [Article Influence: 15.2] [Reference Citation Analysis]
231 Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP. Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk. Arch Gynecol Obstet 2014;289:1079-85. [PMID: 24196303 DOI: 10.1007/s00404-013-3062-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
232 Smith CG. A Resident's Perspective of Ovarian Cancer. Diagnostics (Basel) 2017;7:E24. [PMID: 28448435 DOI: 10.3390/diagnostics7020024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
233 Kesteloot HE, Zhang J. Differences in breast cancer mortality worldwide: unsolved problems: . European Journal of Cancer Prevention 2006;15:416-23. [DOI: 10.1097/00008469-200610000-00006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
234 Ahmed M, Lalloo F, Evans DG. Update on genetic predisposition to breast cancer. Expert Review of Anticancer Therapy 2014;9:1103-13. [DOI: 10.1586/era.09.38] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
235 Yap TA, Smith AD, Ferraldeschi R, Al-lazikani B, Workman P, de Bono JS. Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 2016;15:699-718. [DOI: 10.1038/nrd.2016.120] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
236 Marchetti P, Di Rocco C, Ricevuto E, Bisegna R, Cianci G, Calista F, Sidoni T, Porzio G, Ficorella C. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. Annals of Oncology 2004;15:i27-34. [DOI: 10.1093/annonc/mdh654] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
237 Locke I, Mitchell G, Eeles R. Ductal approaches to assessment and management of women at high risk for developing breast cancer. Breast Cancer Res 2004;6:75-81. [PMID: 14979910 DOI: 10.1186/bcr759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
238 Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:1811-1814. [PMID: 18042939 DOI: 10.1093/jnci/djm203] [Cited by in Crossref: 216] [Cited by in F6Publishing: 141] [Article Influence: 15.4] [Reference Citation Analysis]
239 Gorski JJ, Kennedy RD, Hosey AM, Harkin DP. The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res 2009;15:1514-8. [PMID: 19223511 DOI: 10.1158/1078-0432.CCR-08-0640] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
240 Tripathy S, Gangwar R, Supraja P, Rao AN, Vanjari SRK, Singh SG. Graphene Doped Mn 2 O 3 Nanofibers as a Facile Electroanalytical DNA Point Mutation Detection Platform for Early Diagnosis of Breast/Ovarian Cancer. Electroanalysis 2018;30:2110-20. [DOI: 10.1002/elan.201800220] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
241 Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004;108:479-80. [DOI: 10.1002/ijc.11603] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
242 Rawal R, Bertelsen L, Olsen JH. Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer. Eur J Cancer 2006;42:3034-40. [PMID: 16996259 DOI: 10.1016/j.ejca.2006.04.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
243 Urayama S. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. World J Gastroenterol. 2015;21:1707-1717. [PMID: 25684935 DOI: 10.3748/wjg.v21.i6.1707] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
244 Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:1457-66. [PMID: 18349832 DOI: 10.1038/sj.bjc.6604305] [Cited by in Crossref: 309] [Cited by in F6Publishing: 238] [Article Influence: 23.8] [Reference Citation Analysis]
245 Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers: a review. Breast 2008;17:441-50. [PMID: 18657973 DOI: 10.1016/j.breast.2008.05.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
246 Hemminki K, Chen B. Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database. Prostate 2005;65:188-94. [PMID: 15948149 DOI: 10.1002/pros.20284] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
247 Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JN, Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE, Rubinstein WS, Tung N, Blum JL, Gillen DL. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev 2011;20:1690-702. [PMID: 21708937 DOI: 10.1158/1055-9965.EPI-10-1336] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
248 Gabriel CA, Tigges-cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Familial Cancer 2009;8:23-8. [DOI: 10.1007/s10689-008-9208-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
249 Peters MLB, Tseng JF, Miksad RA. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clinical Therapeutics 2016;38:1622-35. [DOI: 10.1016/j.clinthera.2016.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
250 Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party. Hereditary prostate cancer - Primetime for genetic testing? Cancer Treat Rev 2019;81:101927. [PMID: 31783313 DOI: 10.1016/j.ctrv.2019.101927] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
251 Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther 2007;11:133-44. [PMID: 17570734 DOI: 10.1007/BF03256234] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
252 Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012;12:801-17. [PMID: 23175119 DOI: 10.1038/nrc3399] [Cited by in Crossref: 593] [Cited by in F6Publishing: 497] [Article Influence: 74.1] [Reference Citation Analysis]
253 Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97:476-482. [PMID: 15863147 DOI: 10.1016/j.ygyno.2005.01.024] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
254 Pasanisi P, Bruno E, Manoukian S, Berrino F. A randomized controlled trial of diet and physical activity in BRCA mutation carriers. Fam Cancer 2014;13:181-7. [PMID: 24162448 DOI: 10.1007/s10689-013-9691-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
255 Locker GY, Lynch HT. Genetic factors and colorectal cancer in Ashkenazi Jews. Familial Cancer 2004;3:215-21. [DOI: 10.1007/s10689-004-9547-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
256 Mai PL, Lagos VI, Palomares MR, Weitzel JN. Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. Ann Surg Oncol 2008;15:3415-21. [PMID: 18836779 DOI: 10.1245/s10434-008-0160-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
257 Schrader K, Huntsman D. Hereditary diffuse gastric cancer. Cancer Treat Res 2010;155:33-63. [PMID: 20517687 DOI: 10.1007/978-1-4419-6033-7_3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
258 Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia Pac J Clin Oncol 2011;7:197-211. [PMID: 21884432 DOI: 10.1111/j.1743-7563.2011.01430.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
259 Elmariah SB, Huse J, Mason B, Leroux P, Lustig RA. Multicentric Glioblastoma Multiforme in a Patient with BRCA-1 Invasive Breast Cancer. Breast Journal 2006;12:470-4. [DOI: 10.1111/j.1075-122x.2006.00307.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
260 Kietpeerakool C, Srisomboon J, Phongsaranantakul S, Khunamornpong S, Cheewakriangkrai C, Sribanditmongkol N. Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy: Survival of primary fallopian tube cancer. J Obstet Gynaecol Res 2014;40:806-11. [DOI: 10.1111/jog.12241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
261 Shin EJ, Canto MI. Pancreatic cancer screening. Gastroenterol Clin North Am. 2012;41:143-157. [PMID: 22341255 DOI: 10.1016/j.gtc.2011.12.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
262 Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol 2015;172:1498-506. [PMID: 25524463 DOI: 10.1111/bjd.13626] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
263 Das KK, Early D. Pancreatic cancer screening. Curr Treat Options Gastroenterol. 2017;15:562-575. [PMID: 28879469 DOI: 10.1007/s11938-017-0149-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
264 Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004;23:6445-6470. [PMID: 15322516 DOI: 10.1038/sj.onc.1207714] [Cited by in Crossref: 202] [Cited by in F6Publishing: 140] [Article Influence: 11.9] [Reference Citation Analysis]
265 Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 2008;1138:136-45. [PMID: 18837894 DOI: 10.1196/annals.1414.020] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
266 Schrader KA, Masciari S, Boyd N, Wiyrick S, Kaurah P, Senz J, Burke W, Lynch HT, Garber JE, Huntsman DG. Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 2008;7:73-82. [PMID: 18046629 DOI: 10.1007/s10689-007-9172-6] [Cited by in Crossref: 92] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
267 Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, Tang Y, Yen HY, Stanczyk FZ, Enbom E, Austria T, Widschwendter M, Maxson R, Dubeau L. Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLoS One 2015;10:e0139013. [PMID: 26488398 DOI: 10.1371/journal.pone.0139013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
268 Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005;106:1327-34. [PMID: 16319259 DOI: 10.1097/01.AOG.0000187892.78392.3f] [Cited by in Crossref: 124] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
269 Navarro S, Vaquero E, Maurel J, Bombí JA, De Juan C, Feliu J, Fernández Cruz L, Ginés À, Girela E, Rodríguez R, Sabater L. Recomendaciones para el diagnóstico, la estadificación y el tratamiento del cáncer de páncreas (parte I). Medicina Clínica 2010;134:643-55. [DOI: 10.1016/j.medcli.2009.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
270 Fan H, Zhang Y, Wu D, Ma H, Li X, Li Y, Wang H, Li H, Du B, Wei Q. Construction of label-free electrochemical immunosensor on mesoporous carbon nanospheres for breast cancer susceptibility gene. Analytica Chimica Acta 2013;770:62-7. [DOI: 10.1016/j.aca.2013.01.066] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
271 Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2008;15:21-33. [PMID: 17940826 DOI: 10.1245/s10434-007-9612-4] [Cited by in Crossref: 99] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
272 McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:28-33. [PMID: 15654225 DOI: 10.1097/01.gim.0000151155.36470.ff] [Cited by in Crossref: 57] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
273 Chang MC, Wong JM, Chang YT. Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol. 2014;20:2358-2364. [PMID: 24605033 DOI: 10.3748/wjg.v20.i9.2358] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
274 Qu S, Chen Q, Yi Y, Shao K, Zhang W, Wang Y, Bai J, Li X, Liu Z, Wang X, Jing R, Guan Y, Yi X, Yan M, Cao B, Chen F, Zhu S, Yang X, Wu Y, Huang J. A Reference System for BRCA Mutation Detection Based on Next-Generation Sequencing in the Chinese Population. The Journal of Molecular Diagnostics 2019;21:677-86. [DOI: 10.1016/j.jmoldx.2019.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
275 Rubinstein WS. Roles and responsibilities of a medical geneticist. Fam Cancer 2008;7:5-14. [PMID: 17624600 DOI: 10.1007/s10689-007-9148-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
276 Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet 2020;395:2008-20. [DOI: 10.1016/s0140-6736(20)30974-0] [Cited by in Crossref: 153] [Cited by in F6Publishing: 82] [Article Influence: 153.0] [Reference Citation Analysis]
277 Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA, Daly MB, Godwin AK, Isaacs C, Olopade OI, Tomlinson G, Rubinstein WS, Tung N, Blum JL, Gillen DL. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res 2009;11:R76. [PMID: 19843326 DOI: 10.1186/bcr2414] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
278 Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004;96:15-21. [PMID: 14709734 DOI: 10.1093/jnci/djh008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
279 McCann GA, Eisenhauer EL. Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: surgical options for personalized care. J Surg Oncol 2015;111:118-24. [PMID: 25139656 DOI: 10.1002/jso.23743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
280 Diaconescu S, Gîlcă-blanariu GE, Poamaneagra S, Marginean O, Paduraru G, Stefanescu G. Could the burden of pancreatic cancer originate in childhood? WJG 2021;27:5322-40. [DOI: 10.3748/wjg.v27.i32.5322] [Reference Citation Analysis]
281 Meaney-Delman D, Bellcross CA. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. Obstet Gynecol Clin North Am. 2013;40:475-512. [PMID: 24021253 DOI: 10.1016/j.ogc.2013.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
282 Abdelwahab Yousef AJ. Male Breast Cancer: Epidemiology and Risk Factors. Seminars in Oncology 2017;44:267-72. [DOI: 10.1053/j.seminoncol.2017.11.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
283 Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M. Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Familial Cancer 2009;8:29-32. [DOI: 10.1007/s10689-008-9206-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
284 Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017;8:4008-42. [PMID: 28008141 DOI: 10.18632/oncotarget.14021] [Cited by in Crossref: 78] [Cited by in F6Publishing: 59] [Article Influence: 26.0] [Reference Citation Analysis]
285 Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, Na J, Huang H, Gnanaolivu RD, Larson N, Yussuf A, Yao S, Vachon CM, Trentham-Dietz A, Teras L, Taylor JA, Scott CE, Sandler DP, Pesaran T, Patel AV, Palmer JR, Ong IM, Olson JE, O'Brien K, Neuhausen S, Martinez E, Ma H, Lindstrom S, Le Marchand L, Kooperberg C, Karam R, Hunter DJ, Hodge JM, Haiman C, Gaudet MM, Gao C, LaDuca H, Lacey JV, Dolinsky JS, Chao E, Carter BD, Burnside ES, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Yadav S, Hart SN, Polley EC, Domchek SM, Couch FJ. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. J Clin Oncol 2021;:JCO2100531. [PMID: 34292776 DOI: 10.1200/JCO.21.00531] [Reference Citation Analysis]
286 Zavala VA, Serrano-Gomez SJ, Dutil J, Fejerman L. Genetic Epidemiology of Breast Cancer in Latin America. Genes (Basel) 2019;10:E153. [PMID: 30781715 DOI: 10.3390/genes10020153] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
287 Safra T. Hereditary ovarian cancer: biology, response to chemotherapy and prognosis. Womens Health (Lond) 2009;5:543-53. [PMID: 19702453 DOI: 10.2217/whe.09.40] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
288 Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009;133:365-374. [PMID: 19260742 DOI: 10.1043/1543-2165-133.3.365] [Reference Citation Analysis]
289 Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T. Familial pancreatic cancer: Concept, management and issues. World J Gastroenterol 2017;23:935-48. [PMID: 28246467 DOI: 10.3748/wjg.v23.i6.935] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
290 Grignol VP, Agnese DM. Breast Cancer Genetics for the Surgeon: An Update on Causes and Testing Options. J Am Coll Surg 2016;222:906-14. [PMID: 26968323 DOI: 10.1016/j.jamcollsurg.2016.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
291 Greer JB, Whitcomb DC, Brand RE. Genetic predisposition to pancreatic cancer: a brief review. Am J Gastroenterol. 2007;102:2564-2569. [PMID: 17958761 DOI: 10.1111/j.1572-0241.2007.01475.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
292 Langner C. Hereditäres Magen- und Pankreaskarzinom. Pathologe 2017;38:164-9. [DOI: 10.1007/s00292-017-0297-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
293 Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2011;123:196-9. [PMID: 21855118 DOI: 10.1016/j.ygyno.2011.07.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
294 Fu R, Harris EL, Helfand M, Nelson HD. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med 2007;26:1775-87. [PMID: 17243094 DOI: 10.1002/sim.2811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
295 Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019;119:777-783. [PMID: 30636051 DOI: 10.1002/jso.25376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
296 Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, Cook J, Davidson R, Donaldson A, Eason J, Gregory H, Henderson A, Izatt L, Kennedy MJ, Miller C, Morrison PJ, Murray A, Ong KR, Porteous M, Pottinger C, Rogers MT, Side L, Snape K, Walker L, Tischkowitz M, Eeles R, Easton DF, Antoniou AC. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol 2020;77:24-35. [PMID: 31495749 DOI: 10.1016/j.eururo.2019.08.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
297 Bertagnolli MM. Surgical Prevention of Cancer. JCO 2005;23:324-32. [DOI: 10.1200/jco.2005.08.096] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
298 Reis LO, Dias FG, Castro MA, Ferreira U. Male breast cancer. Aging Male 2011;14:99-109. [PMID: 21204612 DOI: 10.3109/13685538.2010.535048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
299 Kim JW, Cho HJ, Kim M, Lee KH, Kim MA, Han SW, Oh DY, Lee HJ, Im SA, Kim TY, Yang HK, Kim WH, Bang YJ. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. Cancer Chemother Pharmacol. 2013;71:1435-1443. [PMID: 23633032 DOI: 10.1007/s00280-013-2141-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
300 Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, Lynch HT, Friedman E, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10. [PMID: 16962648 DOI: 10.1016/j.ygyno.2006.08.004] [Cited by in Crossref: 100] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
301 Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275. [PMID: 25224030 DOI: 10.1002/cncr.29041] [Cited by in Crossref: 249] [Cited by in F6Publishing: 178] [Article Influence: 35.6] [Reference Citation Analysis]
302 Levy HP, LoPresti L, Seibert DC. Twenty questions in genetic medicine--an assessment of World Wide Web databases for genetics information at the point of care. Genet Med 2008;10:659-67. [PMID: 18978677 DOI: 10.1097/gim.0b013e318180639d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
303 Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HSA, Peeters MV, Rutgers EJT. Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers: Very Low Risk for Subsequent Breast Cancer. Annals of Surgery 2010;251:488-92. [DOI: 10.1097/sla.0b013e3181c3c36d] [Cited by in Crossref: 57] [Cited by in F6Publishing: 10] [Article Influence: 5.2] [Reference Citation Analysis]
304 Meiser B, Cowan R, Costello A, Giles GG, Lindeman GJ, Gaff CL. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake. Urology 2007;70:738-42. [PMID: 17991547 DOI: 10.1016/j.urology.2007.06.1093] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
305 Chun N, Ford JM. Genetic testing by cancer site: stomach. Cancer J. 2012;18:355-363. [PMID: 22846738 DOI: 10.1097/ppo.0b013e31826246dc] [Cited by in Crossref: 52] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
306 O'Quigley J. Faulty BRCA1, BRCA2 genes: how poor is the prognosis? Ann Epidemiol 2017;27:672-6. [PMID: 29017890 DOI: 10.1016/j.annepidem.2017.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Zha N, Alabousi M, Abdullah P, Freitas V, Linthorst R, Muhn N, Alabousi A. Breast Cancer Screening in High-Risk Patients during Pregnancy and Breastfeeding: A Systematic Review of the Literature. Journal of Breast Imaging 2019;1:92-8. [DOI: 10.1093/jbi/wby015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
308 Fasching PA, Bani MR, Nestle-Krämling C, Goecke TO, Niederacher D, Beckmann MW, Lux MP. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. Eur J Cancer Prev 2007;16:216-24. [PMID: 17415092 DOI: 10.1097/CEJ.0b013e32801023b3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
309 Chapa J, Bourgo RJ, Greene GL, Kulkarni S, An G. Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PLoS One 2013;8:e64091. [PMID: 23704974 DOI: 10.1371/journal.pone.0064091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
310 Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010;46:9-20. [PMID: 19926276 DOI: 10.1016/j.ejca.2009.10.021] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 7.6] [Reference Citation Analysis]
311 Zhang YQ, Pilyugin M, Kuester D, Leoni VP, Li L, Casula G, Zorcolo L, Schneider-Stock R, Atzori L, Irminger-Finger I. Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome. Br J Cancer 2012;107:675-83. [PMID: 22814582 DOI: 10.1038/bjc.2012.297] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
312 Dixon SB, Bjornard KL, Alberts NM, Armstrong GT, Brinkman TM, Chemaitilly W, Ehrhardt MJ, Fernandez-pineda I, Force LM, Gibson TM, Green DM, Howell CR, Kaste SC, Kirchhoff AC, Klosky JL, Krull KR, Lucas JT, Mulrooney DA, Ness KK, Wilson CL, Yasui Y, Robison LL, Hudson MM. Factors influencing risk-based care of the childhood cancer survivor in the 21st century: Care of Childhood Cancer Survivors. CA: A Cancer Journal for Clinicians 2018;68:133-52. [DOI: 10.3322/caac.21445] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
313 Katuwal S, Jousilahti P, Pukkala E. Causes of death among women with breast cancer: A follow-up study of 50 481 women with breast cancer in Finland. Int J Cancer 2021. [PMID: 33890290 DOI: 10.1002/ijc.33607] [Reference Citation Analysis]
314 Lowery M, Shah MA, Smyth E, Epstein A, Segal A, Rosengarten O, Isacson R, Drukker L, Keinan A, Rachkiman M, Reissman P, Gabizon A, Kelsen D, O’reilly EM. A 67-Year-Old Woman with BRCA 1 Mutation Associated with Pancreatic Adenocarcinoma. J Gastrointest Canc 2011;42:160-4. [DOI: 10.1007/s12029-010-9197-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
315 Kartal K, Guan Z, Tang R, Griffin M, Wang Y, Braun D, Klein AP, Hughes KS. Familial pancreatic cancer: who should be considered for genetic testing? Ir J Med Sci 2021. [PMID: 33733397 DOI: 10.1007/s11845-021-02572-9] [Reference Citation Analysis]
316 Gorodetska I, Kozeretska I, Dubrovska A. BRCA Genes: The role in genome stability, cancer stemness and therapy resistance. J Cancer. 2019;10:2109-2127. [PMID: 31205572 DOI: 10.7150/jca.30410] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 22.0] [Reference Citation Analysis]
317 Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag 2017;4:13-37. [PMID: 28758010 DOI: 10.2217/mmt-2016-0022] [Cited by in Crossref: 58] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
318 Brand RE, Lynch HT. Genotype/phenotype of familial pancreatic cancer. Endocrinol Metab Clin North Am 2006;35:405-15, xi. [PMID: 16632102 DOI: 10.1016/j.ecl.2006.02.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
319 Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2012;118:493-9. [PMID: 21598239 DOI: 10.1002/cncr.26191] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
320 Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Male breast cancer. Crit Rev Oncol Hematol 2010;73:141-55. [PMID: 19427229 DOI: 10.1016/j.critrevonc.2009.04.003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
321 Li H, Giger ML, Olopade OI, Lan L. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol 2007;14:513-21. [PMID: 17434064 DOI: 10.1016/j.acra.2007.02.003] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
322 Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am 2010;37:109-33, Table of Contents. [PMID: 20494261 DOI: 10.1016/j.ogc.2010.03.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
323 Weitzel JN. The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know. Surg Oncol Clin N Am 2015;24:705-32. [PMID: 26363538 DOI: 10.1016/j.soc.2015.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
324 Collins JM, Isaacs C. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. Breast J 2020;26:1520-7. [PMID: 32652823 DOI: 10.1111/tbj.13970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Sabatier R, Lavit E, Moretta J, Lambaudie E, Noguchi T, Eisinger F, Cherau E, Provansal M, Livon D, Rabayrol L, Popovici C, Charaffe-Jauffret E, Sobol H, Viens P. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Fam Cancer 2016;15:497-506. [PMID: 26833043 DOI: 10.1007/s10689-016-9873-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
326 Yang R, Chen B, Hemminki K, Wappenschmidt B, Engel C, Sutter C, Ditsch N, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Burwinkel B. Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk. Breast Cancer Res Treat 2009;118:407-13. [PMID: 19229607 DOI: 10.1007/s10549-009-0348-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
327 Moiseyenko VM, Volkov NM, Suspistin EN, Yanus GA, Iyevleva AG, Kuligina ESh, Togo AV, Kornilov AV, Ivantsov AO, Imyanitov EN. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Med Oncol. 2013;30:545. [PMID: 23532817 DOI: 10.1007/s12032-013-0545-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
328 Cass I, Walts A, Karlan BY. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? Gynecologic Oncology 2010;117:27-31. [DOI: 10.1016/j.ygyno.2009.12.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
329 Manguoğlu E, Güran S, Yamaç D, Colak T, Simşek M, Baykara M, Akaydın M, Lüleci G. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients. Cancer Genet Cytogenet 2010;203:230-7. [PMID: 21156238 DOI: 10.1016/j.cancergencyto.2010.07.125] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
330 Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol 2010;28:675-82. [PMID: 19841329 DOI: 10.1200/JCO.2008.21.4684] [Cited by in Crossref: 54] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
331 Maccaroni E, Giampieri R, Lenci E, Scortichini L, Bianchi F, Belvederesi L, Brugiati C, Pagliaretta S, Ambrosini E, Berardi R. BRCA mutations and gastrointestinal cancers: When to expect the unexpected? World J Clin Oncol 2021;12:565-80. [PMID: 34367929 DOI: 10.5306/wjco.v12.i7.565] [Reference Citation Analysis]
332 Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist. 2016;21:869-874. [PMID: 27306910 DOI: 10.1634/theoncologist.2015-0354] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
333 de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. Fam Cancer 2015;14:505-13. [PMID: 26026974 DOI: 10.1007/s10689-015-9814-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
334 Son BH, Ahn SH, Kim SW, Kang E, Park SK, Lee MH, Noh WC, Kim LS, Jung Y, Kim KS, Noh DY, Moon BI, Suh YJ, Lee JE, Choi DH, Kim SY, Jung SH, Yom CK, Lee H, Yang JH; KOHBRA Research Group and Korean Breast Cancer Society. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study. Breast Cancer Res Treat 2012;133:1143-52. [PMID: 22382806 DOI: 10.1007/s10549-012-2001-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
335 Chapa J, An G, Kulkarni SA. Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model. PLoS One 2016;11:e0152298. [PMID: 27023391 DOI: 10.1371/journal.pone.0152298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
336 Allain DC. Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn. 2008;10:383-395. [PMID: 18687797 DOI: 10.2353/jmoldx.2008.070161] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
337 Mocellin S, Verdi D, Nitti D. DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis. Carcinogenesis 2009;30:1735-43. [PMID: 19706646 DOI: 10.1093/carcin/bgp207] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
338 Lam TJ, Meurs-Szojda MM, Gundlach L, Belien JA, Meijer GA, Mulder CJ, Felt-Bersma RJ. There is no increased risk for colorectal cancer and adenomas in patients with diverticulitis: a retrospective longitudinal study. Colorectal Dis. 2010;12:1122-1126. [PMID: 19575738 DOI: 10.1111/j.1463-1318.2009.01992.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
339 Aitken L, Warwick L, Davis A. Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines? Intern Med J 2017;47:311-7. [PMID: 28019080 DOI: 10.1111/imj.13357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
340 Huang YW. Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. Medicine (Baltimore) 2018;97:e9380. [PMID: 29480828 DOI: 10.1097/MD.0000000000009380] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
341 Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007;4:578-590. [PMID: 17898808 DOI: 10.1038/ncponc0930] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 6.4] [Reference Citation Analysis]
342 Chhoda A, Lu L, Clerkin BM, Risch H, Farrell JJ. Current approaches to pancreatic cancer screening. Am J Pathol. 2019;189:22-35. [PMID: 30558719 DOI: 10.1016/j.ajpath.2018.09.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
343 Euhus DM. New insights into the prevention and treatment of familial breast cancer. J Surg Oncol 2011;103:294-8. [PMID: 21337561 DOI: 10.1002/jso.21664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
344 Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v23-30. [PMID: 20555088 DOI: 10.1093/annonc/mdq244] [Cited by in Crossref: 127] [Cited by in F6Publishing: 108] [Article Influence: 11.5] [Reference Citation Analysis]
345 Casey MJ, Bewtra C. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Familial Cancer 2004;3:265-81. [DOI: 10.1007/s10689-004-9554-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
346 Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-8. [PMID: 19064968 DOI: 10.1200/JCO.2008.18.5546] [Cited by in Crossref: 136] [Cited by in F6Publishing: 74] [Article Influence: 10.5] [Reference Citation Analysis]
347 Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010;28:2114-22. [PMID: 20308661 DOI: 10.1200/JCO.2009.25.5729] [Cited by in Crossref: 242] [Cited by in F6Publishing: 69] [Article Influence: 22.0] [Reference Citation Analysis]
348 Shukla A, Shukla S, Osowo A, Mashtare T, Bhutani MS, Guha S. Risk of colorectal adenomas in women with prior breast cancer. Dig Dis Sci 2012;57:3240-5. [PMID: 23065089 DOI: 10.1007/s10620-012-2432-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
349 Miller-Samuel S, MacDonald DJ, Weitzel JN, Santiago F, Martino MA, Namey T, Augustyn A, Mueller R, Forman A, Bradbury AR, Morris GJ. Variants of uncertain significance in breast cancer-related genes: real-world implications for a clinical conundrum. Part one: clinical genetics recommendations. Semin Oncol 2011;38:469-80. [PMID: 21810505 DOI: 10.1053/j.seminoncol.2011.04.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
350 Reyna C, Lee MC. Breast cancer in young women: special considerations in multidisciplinary care. J Multidiscip Healthc 2014;7:419-29. [PMID: 25300196 DOI: 10.2147/JMDH.S49994] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
351 Welinsky S, Lucas AL. Familial Pancreatic Cancer and the Future of Directed Screening. Gut Liver 2017;11:761-70. [PMID: 28609837 DOI: 10.5009/gnl16414] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
352 Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007;18 Suppl 6:vi93-8. [PMID: 17591843 DOI: 10.1093/annonc/mdm234] [Cited by in Crossref: 142] [Cited by in F6Publishing: 121] [Article Influence: 10.1] [Reference Citation Analysis]
353 Martin SE, Sausen M, Joseph A, Biggs DD, Kingham BF, Martin ES. BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer. Breast Cancer Res Treat 2009;113:393-5. [DOI: 10.1007/s10549-008-9928-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
354 Kupfer SS, Gupta S, Weitzel JN, Samadder J. AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary. Gastroenterology 2020;159:760-4. [PMID: 32335146 DOI: 10.1053/j.gastro.2020.03.086] [Reference Citation Analysis]
355 Boetes C. Update on Screening Breast MRI in High-Risk Women. Magnetic Resonance Imaging Clinics of North America 2010;18:241-7. [DOI: 10.1016/j.mric.2010.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
356 Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 2018;37:599-614. [PMID: 30232577 DOI: 10.1007/s10555-018-9761-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
357 Ben David MA, Evron E, Rasco AF, Shai A, Corn BW. Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained. Cancers (Basel) 2021;13:2694. [PMID: 34070748 DOI: 10.3390/cancers13112694] [Reference Citation Analysis]
358 Dagan E. Predominant Ashkenazi BRCA1/2 Mutations in Families with Pancreatic Cancer. Genetic Testing 2008;12:267-71. [DOI: 10.1089/gte.2007.0101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]